Cannabidiol Drug Asset Due Diligence Report 2026

This Cannabidiol Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

570

Registered trials

182

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Cannabidiol can convert its Small molecule drug profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cannabidiol (query alias: cannabidiol)
Modality / target	Small molecule drug; Not disclosed; Not disclosed
Highest global status	Approved
Originator	Central South University, Apurano Pharmaceuticals GmbH, Deyi Pharmaceutical Co., Ltd.
Active developers	Cambridge Cognition Ltd., Jazz Pharmaceuticals Research UK Ltd., Autonomous University of Barcelona

The MCP disease footprint includes Tuberous Sclerosis, Epilepsies, Myoclonic, Lennox Gastaut Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07668856	Phase 3	Recruiting	50	Seizure frequency
NCT07624279	Phase 2	Not yet recruiting	80	Moderate-severe headache days
NCT07696871	Phase 1/2	Recruiting	120	Change in Depressive Symptom Severity Assessed by the Hamilton Depression Rating Scale (HAM-17)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Effects of Cannabidiol (CBD) Oral Solution in Patients Undergoing Bilateral Total Knee Arthroplasty: a Randomized, Controlled, Parallel, Triple Blind, Pilot Study

Phase 4; n=37; evaluation: not stated. Reported fields: Cumulative Opioid Usage in First 72 Hours Postoperatively(Mean) = 144.0 Morphine Milligram Equivalents (MME) (Standard Deviation, 77.1); -; -

Cannabidiol Efficacy in Patients with Lennox-Gastaut Syndrome with Developmental and Epileptic Encephalopathy-associated Genetic Variants: A Subgroup Analysis

Not Applicable; n=53; evaluation: Positive. Reported fields: TEAE = 90.9 % ; TEAE = 90.3 %

Sublingual Cannabidiol for Anxiety

Phase 2; n=46; evaluation: not stated. Reported fields: Baseline(Mean) = 21.00 Score (Standard Deviation, 4.10); Baseline(Mean) = 20.97 Score (Standard Deviation, 8.34); -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cannabidiol addresses Tuberous Sclerosis, Epilepsies, Myoclonic, Lennox Gastaut Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 12 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-05-05	Jazz Pharmaceuticals agreement with Nippon Zoki to commercialize Epidyolex in Japan	Approved	Financial terms not disclosed
2025-11-12	Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD	Approved	Financial terms not disclosed
2025-07-29	Ovation Science Expands with Planet 13 into Florida	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of synthesizing cannabidiol, derivatives thereof, and other phytocannabinoids”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO